HARPOON THERAPEUTICS INC's ticker is HARP and the CUSIP is 41358P106. A total of 46 filers reported holding HARPOON THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $710 | -4.6% | 1,000,000 | 0.0% | 0.02% | -50.0% |
| Q1 2023 | $744 | +2.5% | 1,000,000 | 0.0% | 0.04% | +7.3% |
| Q4 2022 | $726 | -99.9% | 1,000,000 | 0.0% | 0.04% | 0.0% |
| Q3 2022 | $970,000 | -49.2% | 1,000,000 | 0.0% | 0.04% | -59.8% |
| Q2 2022 | $1,910,000 | -61.6% | 1,000,000 | 0.0% | 0.10% | -51.0% |
| Q1 2022 | $4,970,000 | -34.2% | 1,000,000 | 0.0% | 0.21% | +1.5% |
| Q4 2021 | $7,550,000 | -4.4% | 1,000,000 | 0.0% | 0.20% | +15.8% |
| Q3 2021 | $7,900,000 | -43.0% | 1,000,000 | 0.0% | 0.18% | -37.2% |
| Q2 2021 | $13,870,000 | -33.7% | 1,000,000 | 0.0% | 0.28% | -23.8% |
| Q1 2021 | $20,920,000 | +57.4% | 1,000,000 | +25.0% | 0.37% | +29.8% |
| Q4 2020 | $13,288,000 | -2.2% | 800,000 | 0.0% | 0.28% | -13.6% |
| Q3 2020 | $13,592,000 | -9.0% | 800,000 | -11.1% | 0.33% | -21.1% |
| Q2 2020 | $14,940,000 | +7.5% | 900,000 | -25.0% | 0.42% | -28.8% |
| Q1 2020 | $13,896,000 | +10.5% | 1,200,000 | +41.2% | 0.59% | +20.8% |
| Q4 2019 | $12,572,000 | – | 850,000 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3,156,699 | $15,689,000 | 7.73% |
| MPM ASSET MANAGEMENT LLC | 3,131,388 | $15,563,000 | 5.32% |
| MPM BioImpact LLC | 3,196,707 | $15,888,000 | 4.26% |
| ACUTA CAPITAL PARTNERS, LLC | 497,500 | $2,473,000 | 1.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,445 | $2,771,000 | 0.62% |
| Orbimed Advisors | 3,039,508 | $15,106,000 | 0.24% |
| Artal Group S.A. | 1,000,000 | $4,970,000 | 0.21% |
| Cormorant Asset Management, LP | 540,600 | $2,687,000 | 0.21% |
| DAFNA Capital Management LLC | 105,163 | $523,000 | 0.14% |
| Ikarian Capital, LLC | 117,009 | $582,000 | 0.08% |